CTLA4 and neoplasm: Next, we calculated the IPS in the POSTN‐high and POSTN‐low expression groups to determine the tumor immunogenicity for predicting response to immune checkpoint inhibitor (ICI) therapy such as CTLA‐4 and PD‐1/PDL1 inhibitors.